Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers

Stefanie Zsch?bitz; Sonia Vallet; Boris Hadaschik; Daniel Debatin; Stefan Fuxius; Andreas Karcher; Sascha Pahernik; Cathleen Spath; Stefan Duensing; Dirk J?ger; Markus Hohenfellner; Carsten Grüllich

首页> 外文期刊>Journal of Cancer >Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers

【24h】

Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers

机译：Cabazitaxel治疗在二次及以后的转移阉割前列腺癌中的疗效。两个德国中心的经历

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: Several new treatment options for patients with metastatic castration resistant prostate cancer (mCRPC) have been approved within the last years - among them cabazitaxel (CAB), abiraterone acetate, enzalutamide, and radium-223. The aim of this study was to assess factors predictive for efficacy of CAB.

机译：目的：在过去几年中，几种新的抗阉割前列腺癌（MCRPC）的新治疗方案已经批准 - 其中Cabazitaxel（驾驶室），AbiraTerone醋酸盐，苯甲酸盐和镭〜223。本研究的目的是评估驾驶室功效预测的因素。

著录项

来源
《Journal of Cancer》 |2017年第4期|共6页
作者
Stefanie Zsch?bitz; Sonia Vallet; Boris Hadaschik; Daniel Debatin; Stefan Fuxius; Andreas Karcher; Sascha Pahernik; Cathleen Spath; Stefan Duensing; Dirk J?ger; Markus Hohenfellner; Carsten Grüllich;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Cabazitaxel after docetaxel: A new option in metastatic castration-resistant prostate cancer [Cabazitaxel après docétaxel, une nouvelle option dans le cancer métastatique de la prostate résistant à la castration] [J] . Bulletin du Cancer: Journal de l'Association Francaise pour l'Etude du Cancer . 2012,第9期

机译：多西他赛后的卡巴他赛：转移性去势抵抗性前列腺癌的新选择[多西他赛后的卡巴他赛，转移性去势抵抗性前列腺癌的新选择]
2. Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO) [J] . Javier Puente, Aranzazu González-del-Alba, Núria Sala-Gonzalez, BMC Cancer . 2019,第1期

机译：AbiraTerone醋酸盐加上泼尼松与Cabazitaxel的疗效和安全性作为后续治疗转移阉割前列腺癌中的后续治疗：结果来自前瞻性观察研究（Capro）
3. No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer [J] . Miyake Hideaki, Sugiyama Takayuki, Aki Ryota, Medical oncology . 2017,第8期

机译：先前治疗概况与多西紫杉醇对日本转移性阉割前列腺癌患者的疗效没有显着影响。
4. Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer: A Decade of Progress and Ongoing Discoveries [C] . Leonel Hernez-Aya, Maha Hussain Genitourinary Cancers Symposium. . 2014

机译：转移激素敏感和阉割的前列腺癌：进步和持续发现的十年
5. Muscle Cross-Sectional Area Is Improved and Physical Funciton Is Maintained After Home-Based Exercise in Men with Metastatic Castration-Resistant Prostate Cancer Undergoing Androgen Deprivation Therapy [D] . Alzer, Mohamdod Saber. 2020

机译：改善肌横截面积，并且在具有转移阉割的前列腺癌接受雄激素剥夺治疗的男性中的男性锻炼之后，将物理静脉凝集维持
6. Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers [O] . Stefanie Zschäbitz, Sonia Vallet, Boris Hadaschik, 2017

机译：卡巴他赛治疗在转移性去势抵抗性前列腺癌中的疗效。来自两个德国中心的经验
7. Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO) [O] . Javier Puente, Aranzazu González-del-Alba, Núria Sala-Gonzalez, 2019

机译：AbiraTerone醋酸盐加上泼尼松与Cabazitaxel的疗效和安全性作为后续治疗转移阉割前列腺癌中的后续治疗：结果来自前瞻性观察研究（Capro）

Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers

摘要

著录项

相似文献

相关主题

期刊订阅